Bianca A. Ulloa

Bianca A. Ulloa

Auto-generated profile, based on publicly available information

Bianca A. Ulloa

Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Cell Reports
Verified
Journal Article
Open access
BUBianca A. Ulloa
Bianca A. Ulloa
SHSamima S. Habbsa
Samima S. Habbsa
KPKathryn S. Potts
Kathryn S. Potts
ALAlana Lewis
Alana Lewis
MMMia McKinstry
Mia McKinstry
TBTeresa Bowman
Teresa Bowman
Hematopoietic stem cells (HSCs) are rare cells that arise in the embryo and sustain adult hematopoiesis. Although the functional potential of nascent HSCs is detectable by transplantation, their native contribution during development is unknown, in part due to the overlapping genesis and marker gene expression with other embryonic blood progenitors. Using single-cell transcriptomics, we define gene signatures that distinguish nascent HSCs from embryonic blood progenitors. Applying a lineage-tracing approach to selectively track HSC output in situ, we find significantly delayed lymphomyeloid contribution. An inducible HSC injury model demonstrates a negligible impact on larval lymphomyelopoiesis following HSC depletion. HSCs are not merely dormant at this developmental stage, as they showed robust regeneration after injury. Combined, our findings illuminate that nascent HSCs self-renew but display differentiation latency, while HSC-independent embryonic progenitors sustain developmental hematopoiesis. Understanding these differences could improve de novo generation and expansion of functional HSCs.

15 October 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
EFEllen Fraint
Ellen Fraint
BUBianca A. Ulloa
Bianca A. Ulloa
MNMaría Feliz Norberto
María Feliz Norberto
KPKathryn S. Potts
Kathryn S. Potts
TBTeresa Bowman
Teresa Bowman
Hematopoietic stem cell transplantation (HSCT) is a treatment for many malignant, congenital, and acquired hematologic diseases. Some outstanding challenges in the HSCT field include the paucity of immunologically-matched donors, our inability to effectively expand hematopoeitic stem cells (HSCs) ex vivo, and the high infection risk during engraftment. Scientists are striving to develop protocols to generate, expand, and maintain HSCs ex vivo, however these are not yet ready for clinical application. Given these problems, advancing our understanding of HSC specification, regulation, and differentiation in preclinical models is essential to improve the therapeutic utility of HSCT. In this review, we link biomedical researchers and transplantation clinicians by discussing the potential therapeutic implications of recent fundamental HSC research in model organisms. We consider deficiencies in current HSCT practice, such as problems achieving adequate cell dose for successful and rapid engraftment, immense inflammatory cascade activation after myeloablation, and graft-vs-host disease. Furthermore, we discuss recent advances in the field of HSC biology and transplantation made in preclinical models of zebrafish, mouse, and nonhuman primates that could inform emerging practice for clinical application.